Immunological and virological mechanisms of vaccine-
HIV

Nature

505, 502-508

DOI: 10.1038/nature12893

Citation Report

#	Article	IF	Citations
2	The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development. Expert Review of Vaccines, 2014, 13, 1489-1500.	2.0	28
3	Progress in HIV-1 vaccine development. Journal of Allergy and Clinical Immunology, 2014, 134, 3-10.	1.5	62
4	Immunomodulation of Antiretroviral Drug-Suppressed Chronic HIV-1 Infection in an Oral Probiotic Double-Blind Placebo-Controlled Trial. AIDS Research and Human Retroviruses, 2014, 30, 988-995.	0.5	56
5	Recombinant Mycobacterium bovis Bacillus Calmette-GuÃ©rin Vectors Prime for Strong Cellular Responses to Simian Immunodeficiency Virus Gag in Rhesus Macaques. Vaccine Journal, 2014, 21, 1385-1395.	3.2	13
6	The influence of delivery vectors on HIV vaccine efficacy. Frontiers in Microbiology, 2014, 5, 439.	1.5	25
7	Importance of neutralization sieve analyses when seeking correlates of HIV-1 vaccine efficacy. Human Vaccines and Immunotherapeutics, 2014, 10, 2507-2511.	1.4	6
8	Therapeutic HIV vaccines: Prior setbacks, current advances, and future prospects. Vaccine, 2014, 32, 5540-5545.	1.7	8
9	HIV-1 vaccines. Human Vaccines and Immunotherapeutics, 2014, 10, 1734-1746.	1.4	30
10	Cure of HIV infection: Is the long wait over?. Journal of Allergy and Clinical Immunology, 2014, 134, 20-22.	1.5	0
11	Immunogen design to focus the B-cell repertoire. Current Opinion in HIV and AIDS, 2014, 9, 217-223.	1.5	13
12	First-in-Human Evaluation of a Hexon Chimeric Adenovirus Vector Expressing HIV-1 Env (IPCAVD 002). Journal of Infectious Diseases, 2014, 210, 1052-1061.	1.9	25
13	Molecularly Tagged Simian Immunodeficiency Virus SIVmac239 Synthetic Swarm for Tracking Independent Infection Events. Journal of Virology, 2014, 88, 8077-8090.	1.5	46
14	The presence of glutamine at position 315 but not epitope masking predominantly hinders HIV subtype C neutralization by the anti-V3 antibody B4e8. Virology, 2014, 462-463, 98-106.	1.1	1
15	Boosting of HIV-1 Neutralizing Antibody Responses by a Distally Related Retroviral Envelope Protein. Journal of Immunology, 2014, 192, 5802-5812.	0.4	4
16	Nonneutralizing Functional Antibodies: a New â€œOldâ€•Paradigm for HIV Vaccines. Vaccine Journal, 2014, 21, 1023-1036.	3.2	107
17	Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay. Journal of Visualized Experiments, 2014, , 51995.	0.2	36
18	Breakthrough Virus Neutralization Resistance as a Correlate of Protection in a Nonhuman Primate Heterologous Simian Immunodeficiency Virus Vaccine Challenge Study. Journal of Virology, 2015, 89, 12388-12400.	1.5	12
19	Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 10780-10785.	3.3	36

#	Article	IF	Citations
20	Surrogates of protection in repeated lowâ€dose challenge experiments. Statistics in Medicine, 2015, 34, 1747-1760.	0.8	5
21	The role of Fc receptors in <scp>HIV</scp> prevention and therapy. Immunological Reviews, 2015, 268, 296-310.	2.8	41
22	Incorporating Founder Virus Information in Vaccine Field Trials. Biometrics, 2015, 71, 386-396.	0.8	8
23	Animal models in HIV-1 protection and therapy. Current Opinion in HIV and AIDS, 2015, 10, 170-176.	1.5	49
24	HIV-1 gp120: A Target for Therapeutics and Vaccine Design. Current Drug Targets, 2015, 17, 122-135.	1.0	19
25	Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies. PLoS ONE, 2015, 10, e0141233.	1.1	10
26	Broadening of Virus-Specific CD8+ T-Cell Responses Is Indicative of Residual Viral Replication in Aviremic SIV Controllers. PLoS Pathogens, 2015, 11, e1005247.	2.1	13
27	Low incidence of HIV infection in an anonymous HIV counselling and testing clinic cohort in Bangkok, Thailand despite high HIV prevalence and self-report of high-risk behaviour. Journal of Virus Eradication, 2015, 1, 78-88.	0.3	0
28	Adenovirus vectors as HIV-1 vaccines. Aids, 2015, 29, 395-400.	1.0	9
29	Bottlenecks in HIV-1 transmission: insights from the study of founder viruses. Nature Reviews Microbiology, 2015, 13, 414-425.	13.6	179
30	Mucosal Immunity and Vaccines Against Simian Immunodeficiency Virus and Human Immunodeficiency Virus. , 2015, , 1171-1182.		1
31	Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost. Journal of Virology, 2015, 89, 6462-6480.	1.5	40
32	Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope. Journal of Virology, 2015, 89, 8130-8151.	1.5	35
33	Vaccine-induced plasmablast responses in rhesus macaques: Phenotypic characterization and a source for generating antigen-specific monoclonal antibodies. Journal of Immunological Methods, 2015, 416, 69-83.	0.6	43
34	Complementary and synergistic activities of anti-V3, CD4bs and CD4i antibodies derived from a single individual can cover a wide range of HIV-1 strains. Virology, 2015, 475, 187-203.	1.1	22
35	Factors influencing frontline health service providersÊ¼ likelihood to recommend a future, preventive HIV vaccine to key populations in Karnataka, south India. Vaccine, 2015, 33, 656-663.	1.7	7
36	The Role of Chance in Primate Lentiviral Infectivity. Progress in Molecular Biology and Translational Science, 2015, 129, 327-351.	0.9	6
37	Elite Control, Gut CD4 T Cell Sparing, and Enhanced Mucosal T Cell Responses in Macaca nemestrina Infected by a Simian Immunodeficiency Virus Lacking a gp41 Trafficking Motif. Journal of Virology, 2015, 89, 10156-10175.	1.5	19

#	Article	IF	Citations
38	Identification, Molecular Cloning, and Analysis of Full-Length Hepatitis C Virus Transmitted/Founder Genotypes 1, 3, and 4. MBio, 2015, 6, e02518.	1.8	15
39	Prospects for a globally effective HIV-1 vaccine. Vaccine, 2015, 33, D4-D12.	1.7	28
40	Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. Science, 2015, 349, 320-324.	6.0	303
42	Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates. Journal of Virology, 2015, 89, 8643-8650.	1.5	42
43	Conserved Molecular Signatures in gp120 Are Associated with the Genetic Bottleneck during Simian Immunodeficiency Virus (SIV), SIV-Human Immunodeficiency Virus (SHIV), and HIV Type 1 (HIV-1) Transmission. Journal of Virology, 2015, 89, 3619-3629.	1.5	22
44	Prospects for a Globally Effective HIV-1 Vaccine. American Journal of Preventive Medicine, 2015, 49, S307-S318.	1.6	29
45	Lessons from the RV144 Thai Phase III HIV-1 Vaccine Trial and the Search for Correlates of Protection. Annual Review of Medicine, 2015, 66, 423-437.	5.0	150
46	Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability. PLoS Pathogens, 2016, 12, e1005537.	2.1	51
47	TRIM5Î± Resistance Escape Mutations in the Capsid Are Transferable between Simian Immunodeficiency Virus Strains. Journal of Virology, 2016, 90, 11087-11095.	1.5	6
48	Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques. Molecular Therapy, 2016, 24, 2021-2032.	3.7	41
49	Designing optimal HIV-vaccine T-cell responses. Current Opinion in HIV and AIDS, 2016, 11, 593-600.	1.5	16
50	Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants. EBioMedicine, 2016, 8, 237-247.	2.7	22
51	Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition. Journal of Immunology, 2016, 197, 2726-2737.	0.4	34
52	High Doses of GM-CSF Inhibit Antibody Responses in Rectal Secretions and Diminish Modified Vaccinia Ankara/Simian Immunodeficiency Virus Vaccine Protection in TRIM5Î±-Restrictive Macaques. Journal of Immunology, 2016, 197, 3586-3596.	0.4	16
53	Derivation and Characterization of Pathogenic Transmitted/Founder Molecular Clones from Simian Immunodeficiency Virus SIVsmE660 and SIVmac251 following Mucosal Infection. Journal of Virology, 2016, 90, 8435-8453.	1.5	19
54	HIV-1 Sequencing. , 2016, , 59-76.		0
56	Lessons from HIV-1 vaccine efficacy trials. Current Opinion in HIV and AIDS, 2016, 11, 607-613.	1.5	21
57	Nonhuman primate models for the evaluation of HIV-1 preventive vaccine strategies. Current Opinion in HIV and AIDS, 2016, 11, 546-554.	1.5	40

#	Article	IF	Citations
58	Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection. Molecular Therapy, 2016, 24, 832-842.	3.7	107
59	Approaches to preventative and therapeutic HIV vaccines. Current Opinion in Virology, 2016, 17, 104-109.	2.6	72
60	HIV-Host Interactions: Implications for Vaccine Design. Cell Host and Microbe, 2016, 19, 292-303.	5.1	143
61	Evaluation of the maturation of individual Dengue virions with flow virometry. Virology, 2016, 488, 20-27.	1.1	30
62	Signatures in Simian Immunodeficiency Virus SIVsmE660 Envelope gp120 Are Associated with Mucosal Transmission but Not Vaccination Breakthrough in Rhesus Macaques. Journal of Virology, 2016, 90, 1880-1887.	1.5	15
63	Single-Genome Sequencing of Hepatitis C Virus in Donor-Recipient Pairs Distinguishes Modes and Models of Virus Transmission and Early Diversification. Journal of Virology, 2016, 90, 152-166.	1.5	17
64	Systems serology for evaluation of <scp>HIV</scp> vaccine trials. Immunological Reviews, 2017, 275, 262-270.	2.8	69
65	Polyvalent vaccine approaches to combat <scp>HIV</scp>â€1 diversity. Immunological Reviews, 2017, 275, 230-244.	2.8	46
66	Survivors Remorse: antibodyâ€mediated protection against <scp>HIV</scp>â€1. Immunological Reviews, 2017, 275, 271-284.	2.8	25
67	Modified Vaccinia Virus Ankara. Advances in Virus Research, 2017, 97, 187-243.	0.9	233
68	Monoclonal Antibodies Specific for the V2, V3, CD4-Binding Site, and gp41 of HIV-1 Mediate Phagocytosis in a Dose-Dependent Manner. Journal of Virology, 2017, 91, .	1.5	48
69	Synthetic biology approach for the development of conditionally replicating HIV-1 vaccine. Journal of Chemical Technology and Biotechnology, 2017, 92, 455-462.	1.6	4
70	HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates. Journal of Virology, 2017, 91, .	1.5	26
71	Adenovirus prime, Env protein boost vaccine protects against neutralization-resistant SIVsmE660 variants in rhesus monkeys. Nature Communications, 2017, 8, 15740.	5.8	11
72	Conserved signatures indicate HIV-1 transmission is under strong selection and thus is not a â€œstochasticâ€•process. Retrovirology, 2017, 14, 13.	0.9	6
73	Functional Stability of HIV-1 Envelope Trimer Affects Accessibility to Broadly Neutralizing Antibodies at Its Apex. Journal of Virology, 2017, 91, .	1.5	19
74	Vector Order Determines Protection against Pathogenic Simian Immunodeficiency Virus Infection in a Triple-Component Vaccine by Balancing CD4 ⁺ and CD8 ⁺ T-Cell Responses. Journal of Virology, 2017, 91, .	1.5	6
75	Novel Concepts for HIV Vaccine Vector Design. MSphere, 2017, 2, .	1.3	11

#	Article	IF	Citations
76	Altered regional homogeneity of brain spontaneous signals in SIV infected rhesus macaque model. Magnetic Resonance Imaging, 2017, 37, 56-61.	1.0	7
77	HIV Vaccines. , 2017, , 829-834.e1.		0
78	Structure-based Design of Cyclically Permuted HIV-1 gp120 Trimers That Elicit Neutralizing Antibodies. Journal of Biological Chemistry, 2017, 292, 278-291.	1.6	18
79	Immunologic and Virologic Mechanisms for Partial Protection from Intravenous Challenge by an Integration-Defective SIV Vaccine. Viruses, 2017, 9, 135.	1.5	3
80	Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates. Journal of Virology, 2018, 92, .	1.5	10
81	Nonhuman primate models of human viral infections. Nature Reviews Immunology, 2018, 18, 390-404.	10.6	151
82	What Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans?. Cold Spring Harbor Perspectives in Biology, 2018, 10, a029504.	2.3	23
83	Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV. Nature Medicine, 2018, 24, 1590-1598.	15.2	129
84	Gag and env conserved element CE DNA vaccines elicit broad cytotoxic T cell responses targeting subdominant epitopes of HIV and SIV Able to recognize virus-infected cells in macaques. Human Vaccines and Immunotherapeutics, 2018, 14, 2163-2177.	1.4	14
85	Control of Heterologous Simian Immunodeficiency Virus SIV _{smE660} Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques. Journal of Virology, 2018, 92, .	1.5	39
87	Immune Correlate-Guided HIV Vaccine Design. Cell Host and Microbe, 2018, 24, 25-33.	5.1	44
88	Monkey Models and HIV Vaccine Research. Advances in Experimental Medicine and Biology, 2018, 1075, 97-124.	0.8	11
89	V2-Specific Antibodies in HIV-1 Vaccine Research and Natural Infection: Controllers or Surrogate Markers. Animals, 2019, 9, 526.	1.0	11
90	V2-Specific Antibodies in HIV-1 Vaccine Research and Natural Infection: Controllers or Surrogate Markers. Vaccines, 2019, 7, 82.	2.1	11
91	Vaccination of Macaques with DNA Followed by Adenoviral Vectors Encoding Simian Immunodeficiency Virus (SIV) Gag Alone Delays Infection by Repeated Mucosal Challenge with SIV. Journal of Virology, 2019, 93, .	1.5	5
92	Multimeric Epitope-Scaffold HIV Vaccines Target V1V2 and Differentially Tune Polyfunctional Antibody Responses. Cell Reports, 2019, 28, 877-895.e6.	2.9	36
93	A Sample-Sparing Multiplexed ADCP Assay. Frontiers in Immunology, 2019, 10, 1851.	2.2	42
94	Isolation and Structure of an Antibody that Fully Neutralizes Isolate SIVmac239 Reveals Functional Similarity of SIV and HIV Glycan Shields. Immunity, 2019, 51, 724-734.e4.	6.6	13

#	Article	IF	Citations
95	Revisiting the Correlate of Reduced HIV Infection Risk in the Rv144 Vaccine Trial. Journal of Virology, 2019, 93, .	1.5	7
96	The Antibodiomeâ€"Mapping the Humoral Immune Response to HIV. Current HIV/AIDS Reports, 2019, 16, 169-179.	1.1	13
97	Recombinant HIV-1 vaccine candidates based on replication-defective flavivirus vector. Scientific Reports, 2019, 9, 20005.	1.6	10
98	Vaccine-induced V1V2-specific antibodies control and or protect against infection with HIV, SIV and SHIV. Current Opinion in HIV and AIDS, 2019, 14, 309-317.	1.5	25
99	Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers. Immunity, 2019, 50, 241-252.e6.	6.6	153
100	A high throughput lentivirus sieving assay identifies neutralization resistant Envelope sequences and predicts in vivo sieving. Journal of Immunological Methods, 2019, 464, 64-73.	0.6	2
101	Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques. Cell, 2020, 183, 185-196.e14.	13.5	25
102	Search for antiviral functions of potentially protective antibodies against V2 region of HIV-1. Human Vaccines and Immunotherapeutics, 2020, 16, 2033-2041.	1.4	2
103	Priming with DNA Expressing Trimeric HIV V1V2 Alters the Immune Hierarchy Favoring the Development of V2-Specific Antibodies in Rhesus Macaques. Journal of Virology, 2020, 95, .	1.5	5
104	Env diversity-dependent protection of the attenuated equine infectious anaemia virus vaccine. Emerging Microbes and Infections, 2020, 9, 1309-1320.	3.0	13
105	Impact of the expression system on the immune responses to self-assembling protein nanoparticles (SAPNs) displaying HIV-1 V1V2 loop. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 29, 102255.	1.7	5
106	Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention. Annual Review of Immunology, 2020, 38, 673-703.	9.5	74
107	Threshold dynamics of a general delayed within-host viral infection model with humoral immunity and two modes of virus transmission. Discrete and Continuous Dynamical Systems - Series B, 2021, 26, 3835.	0.5	1
108	Long-acting injectable HIV therapies: the next frontier. Current Opinion in Infectious Diseases, 2021, 34, 8-15.	1.3	11
109	Long-acting injectable HIV therapies: the next frontier: Republication. Current Opinion in HIV and AIDS, 2021, 16, 98-105.	1.5	4
110	Oral Vaccination Approaches for Anti-SHIV Immunity. Frontiers in Immunology, 2021, 12, 702705.	2.2	2
112	The mechanistic analysis of founder virus data inÂchallenge models. Statistics in Medicine, 2021, 40, 4492-4504.	0.8	2
114	Threshold dynamics of an HIV-1 virus model with both virus-to-cell and cell-to-cell transmissions, intracellular delay, and humoral immunity. Applied Mathematics and Computation, 2017, 315, 516-530.	1.4	59

#	Article	IF	Citations
115	Glycopeptide epitope facilitates HIV-1 envelope specific humoral immune responses by eliciting T cell help. Nature Communications, 2020, 11, 2550.	5.8	17
116	HIV vaccine delayed boosting increases Env variable region 2â€“specific antibody effector functions. JCI Insight, 2020, 5, .	2.3	18
117	SIV infection duration largely determines broadening of neutralizing antibody response in macaques. Journal of Clinical Investigation, 2020, 130, 5413-5424.	3.9	2
118	AAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing Activity. PLoS Pathogens, 2015, 11, e1005090.	2.1	77
119	Parsimonious Determination of the Optimal Infectious Dose of a Pathogen for Nonhuman Primate Models. PLoS Pathogens, 2015, 11, e1005100.	2.1	13
120	Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. PLoS Pathogens, 2017, 13, e1006074.	2.1	33
121	Vaccine-induced immune responses against both Gag and Env improve control of simian immunodeficiency virus replication in rectally challenged rhesus macaques. PLoS Pathogens, 2017, 13, e1006529.	2.1	19
122	Use of Dried Blood Spots to Elucidate Full-Length Transmitted/Founder HIV-1 Genomes. Pathogens and Immunity, 2016, 1, 129.	1.4	9
123	HIV-specific ADCC: preventive and therapeutic vaccine potential. Microbiology Australia, 2014, 35, 105.	0.1	0
124	Multimeric Epitope-Scaffold HIV Vaccines Target V1V2 and Differentially Tune Polyfunctional Antibody Responses. SSRN Electronic Journal, 0, , .	0.4	0
126	New prospects for a preventive HIV-1 vaccine. Journal of Virus Eradication, 2015, 1, 78-88.	0.3	1
127	Structure and Fc-Effector Function of Rhesusized Variants of Human Anti-HIV-1 IgG1s. Frontiers in Immunology, 2021, 12, 787603.	2.2	1
128	Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines. Nature Communications, 2022, 13, 903.	5.8	7
129	Reappraising the Value of HIV-1 Vaccine Correlates of Protection Analyses. Journal of Virology, 2022, , e0003422.	1.5	7
131	A clade C HIV-1 vaccine protects against heterologous SHIV infection by modulating IgG glycosylation and T helper response in macaques. Science Immunology, 2022, 7, .	5.6	7
132	Stabilized HIV-1 envelope immunization induces neutralizing antibodies to the CD4bs and protects macaques against mucosal infection. Science Translational Medicine, 2022, 14, .	5.8	15
133	Molecular insights into antibody-mediated protection against the prototypic simian immunodeficiency virus. Nature Communications, 2022, 13, .	5.8	3
134	Cryo-EM structures of prefusion SIV envelope trimer. Nature Structural and Molecular Biology, 2022, 29, 1080-1091.	3.6	7

#	Article	IF	Citations
135	Genetic stability of SIV Gag/Tat gene inserted into Del-II in modified vaccinia virus ankara after serial passage of recombinant vector in pCEFs cells. Journal of Virological Methods, 2023, 312, 114651.	1.0	2
136	Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults. Journal of Clinical Investigation, 2023, 133, .	3.9	4